Mutual of America Capital Management LLC Sells 1,716 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Mutual of America Capital Management LLC decreased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 8.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 19,276 shares of the medical research company’s stock after selling 1,716 shares during the period. Mutual of America Capital Management LLC’s holdings in NeoGenomics were worth $284,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of NEO. First Light Asset Management LLC lifted its stake in shares of NeoGenomics by 14.5% during the 2nd quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock valued at $52,464,000 after buying an additional 480,396 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of NeoGenomics by 7.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,324,624 shares of the medical research company’s stock valued at $46,108,000 after acquiring an additional 217,687 shares in the last quarter. American Century Companies Inc. grew its stake in NeoGenomics by 5.4% in the 2nd quarter. American Century Companies Inc. now owns 3,261,756 shares of the medical research company’s stock worth $45,241,000 after buying an additional 167,145 shares in the last quarter. Sei Investments Co. increased its stake in NeoGenomics by 152.6% in the second quarter. Sei Investments Co. now owns 263,761 shares of the medical research company’s stock valued at $3,658,000 after acquiring an additional 159,350 shares during the last quarter. Finally, Candriam S.C.A. lifted its stake in NeoGenomics by 29.9% during the second quarter. Candriam S.C.A. now owns 487,026 shares of the medical research company’s stock worth $6,755,000 after purchasing an additional 112,009 shares during the last quarter. 98.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on NEO shares. Needham & Company LLC reissued a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a research note on Wednesday, November 6th. Benchmark restated a “buy” rating and set a $18.00 price target on shares of NeoGenomics in a report on Tuesday, September 24th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $20.25.

NeoGenomics Trading Up 3.3 %

Shares of NASDAQ NEO opened at $17.74 on Friday. The company has a market cap of $2.28 billion, a PE ratio of -29.08 and a beta of 1.19. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. The firm’s 50 day moving average price is $14.72 and its 200-day moving average price is $14.89. NeoGenomics, Inc. has a 52-week low of $12.77 and a 52-week high of $21.22.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. The firm had revenue of $167.80 million during the quarter, compared to analyst estimates of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.06) earnings per share. On average, equities research analysts expect that NeoGenomics, Inc. will post -0.17 EPS for the current fiscal year.

Insider Transactions at NeoGenomics

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the company’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the transaction, the general counsel now owns 37,129 shares of the company’s stock, valued at approximately $570,301.44. This represents a 12.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 1.30% of the stock is currently owned by company insiders.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.